SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LJM who wrote (11241)8/16/1999 6:20:00 PM
From: Jim Haynes  Respond to of 17367
 
At the annual meeting, Castello mentioned that, because it takes time to get m/c patients enrolled and it is a very fast progressing disease, some of the Neuprex patients may have been too far gone to derive any benefit. Could this account for what we SPECULATE may be positive but statistically weak results? I was interested in Castello's emphasis in the c/c on the trauma trial being prophylactic. That should obviate the too late problem.

Jim Haynes



To: LJM who wrote (11241)8/16/1999 6:21:00 PM
From: aknahow  Read Replies (2) | Respond to of 17367
 
Yours would have been the best question of all.

I did press 31 to get into que but they took the guy that post on Yahoo, without any question. Mine would not have been as good as yours. Would have asked, "At the annual meeting you said there were 34 deaths in the trial. How many of those deaths occurred in the placebo arm?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News